SCHEMBL4677283

SCHEMBL4677283

CCOC(=O)CCc1cc(OC)c(S(=O)(=O)Cl)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
HTR2A P28223 4/20 0.42
HTR2C P28335 3/20 0.41
HTR2B P41595 3/20 0.41
DPP4 P27487 1/20 0.40
TRPV4 Q9HBA0 1/20 0.39
TSHR P16473 1/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
TNF P01375 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679593 0.95 CYP4F2 (0.43) CYP4F2CYP4A11HTR2AHTR2CHTR2B
SCHEMBL17722574 0.86 CYP4F2 (0.54) CYP4F2CYP4A11DPP4ALDH1A1KDM4E
SCHEMBL490753 0.83 CYP4F2 (0.51) CYP4F2CYP4A11DPP4ALDH1A1KDM4E
SCHEMBL14102272 0.82 CYP4F2 (0.43) CYP4F2CYP4A11HTR2AHTR2CHTR2B
SCHEMBL17718565 0.80 CYP4F2 (0.49) CYP4F2CYP4A11DPP4ALDH1A1KDM4E
SCHEMBL4733364 0.78 CYP4F2 (0.47) CYP4F2CYP4A11DPP4ALDH1A1KDM4E
SCHEMBL27621736 0.77 HTR2A (0.43) HTR2AHTR2CHTR2BTRPV4ALDH1A1
SCHEMBL31295082 0.76 CYP4F2 (0.48) CYP4F2CYP4A11DPP4ALDH1A1KDM4E
SCHEMBL4674697 0.75 CYP4F2 (0.47) CYP4F2CYP4A11DPP4ALDH1A1KDM4E
SCHEMBL10604296 0.74 CYP4F2 (0.49) CYP4F2CYP4A11DPP4ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482935-B1 THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY WARNER LAMBERT CO (US) 2008-08-20 EP disclosed
EP-1482935-A1 THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY Warner-Lambert Company LLC (US) 2004-12-08 EP disclosed
US-20030207924-A1 Compounds that modulate PPAR activity and methods of preparation CHENG XUE-MIN (US) 2003-11-06 US disclosed
WO-2003074050-A1 THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY WARNER-LAMBERT COMPANY LLC (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207924-A1 Compounds that modulate PPAR activity and methods of preparation PPARA, PPARD, PPARG CYP4F2 968/4885CYP4A11 207/4885HTR2A 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.